Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment
International Journal of Molecular Sciences · 09.05.2025 · 26 (10) · 4509
DOI: 10.3390/ijms26104509 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2025. Verfasst von Xiangning Cheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Hauptthemen laut MEDLINE: Rhinitis, Allergic, Biological Products. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key Research and Development Program of China, the National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Allergic rhinitis (AR) is a common and increasingly prevalent chronic inflammatory disorder of the nasal mucosa that severely impacts patients’ quality of life, causing symptoms like nasal congestion, sneezing, and itching. AR is primarily mediated by immunoglobulin E (IgE) when allergens are present, making it challenging to manage despite available therapies like pharmacotherapy, immunotherapy, and surgery. Recently, research has focused on biologics as an emerging therapeutic option for AR. Biologics target specific immune pathways in type 2 inflammation, which underlies many allergic diseases including AR. Biologics offer a targeted and potentially more effective alternative to traditional therapies, addressing the underlying immune mechanisms rather than simply alleviating symptoms. Based on key clinical trial evidence, this paper tentatively proposes a multidimensional strategy for selecting biologics in AR, integrating serum IgE levels, disease phenotypes (seasonal/persistent), and comorbid characteristics to guide individualized treatment. However, the long-term cost-effectiveness, optimal dosing regimens, and patient adherence to biologics require further validation through real-world data. Despite these challenges, recent advancements in biologics represent a promising step forward in AR management. With ongoing research and clinical trials, biologics may soon provide more effective and lasting relief for patients suffering from allergic rhinitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Förderung
- the National Key Research and Development Program of China
- the National Natural Science Foundation of China
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Cheng, X., Zhou, Y., Hao, Y., Long, Z., Hu, Q., Huo, B., Xie, T., Chen, S., Zhou, L., Zhou, T., Li, L., Cheng, Q., & Chen, J. (2025). Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment. International Journal of Molecular Sciences, 26(10), 4509. https://doi.org/10.3390/ijms26104509
Vancouver
Cheng X, Zhou Y, Hao Y, Long Z, Hu Q, Huo B, et al. Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment. International Journal of Molecular Sciences. 2025;26(10):4509. doi:10.3390/ijms26104509
BibTeX
@article{Cheng2025,
author = {Cheng, Xiangning and Zhou, Yue and Hao, Yuzhe and Long, Ziyi and Hu, Qianxue and Huo, Bingyue and Xie, Tianjian and Chen, Shan and Zhou, Liuqing and Zhou, Tao and Li, Liyue and Cheng, Qing and Chen, Jianjun},
title = {Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {10},
pages = {4509},
doi = {10.3390/ijms26104509}
}
EUVIMED